- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01888185
Identifying Biomarkers of Parkinson's Disease Using Magnetic Resonance Imaging (MRI)
2. ledna 2020 aktualizováno: Xuemei Huang, MD, PhD, Milton S. Hershey Medical Center
Multimodal MRI Markers of Nigrostriatal Pathology in Parkinson's Disease
This study is designed to determine if magnetic resonance imaging (MRI) measures can be used to diagnose and monitor the progression of Parkinson's disease (PD) while distinguishing between PD and parkinsonisms [conditions that are PD look-a-like diseases such as progressive supranuclear palsy (PSP) or multiple system atrophy (MSA)] when combined with changes in certain proteins in body fluids that are related to iron (Fe).
Přehled studie
Postavení
Dokončeno
Detailní popis
The lack of in vivo biomarker(s) reflecting Parkinson's disease (PD)-related cell loss and associated pathoetiological/physiological processes in nigrostriatal structures has hindered discovery research and limited the ability to evaluate disease-modifying therapies.
Recent research has generated excitement for using DTI and R2* MRI measures as biomarker(s) for PD-related pathology in nigrostriatal pathways, but they fall short by the lack of understanding of their clinical implications and biological/pathological underpinnings.
Working closely with the National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Biomarkers Program (PDBP), the proposed work will investigate multimodal MRI techniques in combination with fluid-based iron (Fe) protein profiles to serve as in vivo markers for PD-related nigrostriatal pathology that can be used as biomarkers for diagnosing PD, following its progression, and gaining mechanistic understanding of PD pathoetiology and pathophysiology.
Typ studie
Pozorovací
Zápis (Aktuální)
290
Kontakty a umístění
Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.
Studijní místa
-
-
Pennsylvania
-
Hershey, Pennsylvania, Spojené státy, 17033
- Penn State Milton S. Hershey Medical Center and College of Medicine
-
-
Kritéria účasti
Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.
Kritéria způsobilosti
Věk způsobilý ke studiu
21 let až 90 let (Dospělý, Starší dospělý)
Přijímá zdravé dobrovolníky
Ano
Pohlaví způsobilá ke studiu
Všechno
Metoda odběru vzorků
Vzorek nepravděpodobnosti
Studijní populace
Clinical patients and community volunteers
Popis
Inclusion Criteria:
PD Subjects:
- Able and willing to sign the consent form at time of initial enrollment or if the subject is decisionally impaired and has a legal representative that is able and willing to sign a consent form at the time of the enrollment. If the subject becomes decisionally impaired during the course of the study, their legal representative may sign an addendum to consent for continued participation.
- MMSE score of 15 or greater unless a legal representative is present.
- Idiopathic PD according to published criteria.
- History of adequate response to dopaminergic therapy.
- History of asymmetrical symptom onset
MSA Subjects:
- Older than 30 yrs.
- Able and willing to sign the consent form at time of initial enrollment or if the subject is decisionally impaired and has a legal representative that is able and willing to sign a consent form at the time of the enrollment. If the subject becomes decisionally impaired during the course of the study, their legal representative may sign an addendum to consent for continued participation.
- MMSE score of 15 or greater unless a legal representative is present.
- MSA according to published criteria.
- History of autonomic & urinary dysfunction and/or severe cerebellar ataxia.
PSP Subjects:
- Older than 40 yrs.
- Able and willing to sign the consent form at time of initial enrollment or if the subject is decisionally impaired and has a legal representative that is able and willing to sign a consent form at the time of the enrollment. If the subject becomes decisionally impaired during the course of the study, their legal representative may sign an addendum to consent for continued participation.
- PSP according to published criteria.
- Vertical gaze palsy and/or slow vertical gaze/postural instability during first year of diagnosis.
- MMSE score of 15 or greater unless a legal representative is present
Controls:
- Older than 21 yrs.
- Able and willing to sign the consent form.
- MMSE greater than 24.
Exclusion Criteria:
PD Subjects:
- Unable or does not have a legal representative/unwilling to provide consent.
- Any condition that precludes a routine MRI (e.g., claustrophobia, pacemaker, severe scoliosis, etc.).
- History of cerebrovascular diseases or other neurological disorders.
- Major medical problems such as renal or liver failure.
- Unstable, non-PD-related medical conditions.
- MMSE score less than 15 unless a legal representative is present
- Use of anticoagulant medications.
- Signs of dementia.
MSA Subjects:
- Unable or does not have a legal representative /unwilling to provide consent.
- Any condition that precludes a routine MRI (e.g., claustrophobia, pacemaker, severe scoliosis, etc.).
- History of cerebrovascular diseases or other neurological disorders.
- Major medical problems such as renal or liver failure.
- Unstable, non-MSA-related medical conditions.
- MMSE score less than 15 unless a legal representative is present
- Use of anticoagulant medications.
- Signs of dementia.
PSP Subjects:
- Unable or does not have a legal representative /unwilling to provide consent.
- Any condition that precludes a routine MRI (e.g., claustrophobia, pacemaker, severe scoliosis, etc.).
- History of cerebrovascular diseases or other neurological disorders.
- Major medical problems such as renal or liver failure.
- Unstable, non-PSP-related medical conditions.
- MMSE score less than 15 unless a legal representative is present
- Use of anticoagulant medications.
- Signs of dementia.
Controls:
- Unable/unwilling to provide consent.
- Evidence of severe memory impairment or signs of dementia (MMSE < 24).
- Any condition that precludes a routine MRI (e.g., claustrophobia, pacemaker, severe scoliosis, etc.).
- History of cerebrovascular diseases or other neurological disorders.
- Major medical problems such as renal or liver failure.
- Unstable medical conditions.
- Use of anticoagulant medications.
- Signs of dementia.
Studijní plán
Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.
Jak je studie koncipována?
Detaily designu
Kohorty a intervence
Skupina / kohorta |
---|
Parkinson's Disease (PD)
Patients with a clinical diagnosis of PD (in various stages)
|
Progressive supranuclear palsy (PSP)
Patients with a clinical diagnosis of PSP (in various stages)
|
Multiple system atrophy (MSA)
Patients with a clinical diagnosis of MSA (in various stages)
|
Controls
Age and gender-matched adults free from neurological disease
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Differential roles of fractional anisotropy (FA) and R2* in PD detection and progression
Časové okno: Change in roles of FA and R2* assessed between baseline and 18 months. Change assessed between baseline and 36 months. Change assessed between 18 and 36 months.
|
Substantia Nigra (SN) FA and R2* values in PD subjects will be compared with control subjects and correlated with clinical and behavioral measures.
|
Change in roles of FA and R2* assessed between baseline and 18 months. Change assessed between baseline and 36 months. Change assessed between 18 and 36 months.
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Nigrostriatal diffusion tensor imaging (DTI) and R2* differentiate PD from parkinsonian syndromes
Časové okno: Assessed at baseline visit.
|
DTI and R2* measures in both SN and striatal structures in PD, PSP, MSA and control subjects will be compared to assess sensitivity and specificity of individual and combined MRI measures in diagnosing PD.
|
Assessed at baseline visit.
|
Iron(Fe)-related proteins in body fluids as biomarkers of PD
Časové okno: Change assessed between baseline and 18 months. Change assessed between baseline and 36 months. Change assessed between 18 and 36 months.
|
The protein profile in blood, urine, and cerebral spinal fluid (CSF), and their relationships to clinical and MRI measure will be interrogated with the focus being on Fe-related proteins such as hepcidin, ferritin, and transferrin.
|
Change assessed between baseline and 18 months. Change assessed between baseline and 36 months. Change assessed between 18 and 36 months.
|
MRI and postmortem pathological correlation
Časové okno: From baseline until date of death from any cause within 5 years for patient participants who succumb to their disease
|
Postmortem brain analysis on patients who succumb to their disease during the study will be performed in order to inform the relationship of the biomarkers to clinical diagnosis (PD, PSP, MSA) and clinical milestones as well as to inform the pathological underpinnings of the R2* and DTI measures.
In addition to standard postmortem diagnostic tests (alpha-synuclein, beta-amyloid, tau, and ubiquitin), total Fe staining, ferritin, hepcidin, tyrosine hydroxylase positive neurons, myelin and glial derived growth factors (glial cell markers) will be assessed in nigrostriatal structures in order to correlate these levels with MRI measures.
|
From baseline until date of death from any cause within 5 years for patient participants who succumb to their disease
|
Spolupracovníci a vyšetřovatelé
Zde najdete lidi a organizace zapojené do této studie.
Sponzor
Publikace a užitečné odkazy
Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.
Termíny studijních záznamů
Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.
Hlavní termíny studia
Začátek studia
1. prosince 2012
Primární dokončení (Aktuální)
1. prosince 2019
Dokončení studie (Aktuální)
31. prosince 2019
Termíny zápisu do studia
První předloženo
17. ledna 2013
První předloženo, které splnilo kritéria kontroly kvality
25. června 2013
První zveřejněno (Odhad)
27. června 2013
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
3. ledna 2020
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
2. ledna 2020
Naposledy ověřeno
1. ledna 2020
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Kardiovaskulární choroby
- Cévní onemocnění
- Onemocnění mozku
- Onemocnění centrálního nervového systému
- Nemoci nervového systému
- Oční nemoci
- Neurologické projevy
- Bazální gangliové choroby
- Poruchy pohybu
- Synukleinopatie
- Neurodegenerativní onemocnění
- Tauopatie
- Onemocnění kraniálních nervů
- Onemocnění autonomního nervového systému
- Poruchy oční motility
- Ochrnutí
- Primární dysautonomie
- Hypotenze
- Oftalmoplegie
- Parkinsonova choroba
- Mnohonásobná systémová atrofie
- Syndrom Shy-Drager
- Parkinsonské poruchy
- Supranukleární obrna, progresivní
Další identifikační čísla studie
- MSHersheyMC-40726
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .